<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="inhibit">
<roleset id="inhibit.01" name="" wordnet="2">
<roles>
  <role n="0" descr="agent
"/>
  <role n="1" descr="the entity being inhibited by agent to get binding
"/>
  <role n="2" descr="the action or property being inhibited
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
This synthetic peptide bound to P and inhibited its binding to C3b.

</text>
       <arg n="0">This synthetic peptide
</arg>
       <arg n="1">P
</arg>
       <arg n="2">its binding to C3b
</arg>
<fdg>
         1	This	this	det:&gt;3	@DN&gt; %&gt;N DET DEM SG
         2	synthetic	synthetic	attr:&gt;3	@A&gt; %&gt;N A ABS
         3	peptide	peptide	subj:&gt;4	@SUBJ %NH N NOM SG
         4	bound	bind	main:&gt;0	@+FMAINV %VA V PAST
         5	to	to	ha:&gt;4	@ADVL %EH PREP
         6	P	p	pcomp:&gt;5	@&lt;P %NH ABBR NOM SG
         7	and	and	cc:&gt;4	@CC %CC CC
         8	inhibited	inhibit	cc:&gt;4	@+FMAINV %VA V PAST
         9	its	it	attr:&gt;10	@A&gt; %&gt;N PRON GEN SG3
         10	binding	binding	obj:&gt;8	@OBJ %NH N NOM SG
         11	to	to	goa:&gt;8	@ADVL %EH PREP
         12	C3b	c3b	pcomp:&gt;11	@&lt;P %NH N NOM SG
         13	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms that are inhibited by rolipram.

</text>
       <arg n="0">[by] rolipram
</arg>
       <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms
</arg>
       <arg n="2">-
</arg>
<fdg>
         1	PDE4C	pde4c	subj:&gt;2	@SUBJ %NH N NOM SG
         2	is	be	main:&gt;0	@+FMAINV %VA V PRES SG3
         3	one	one	comp:&gt;2	@PCOMPL-S %NH NUM CARD
         4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
         5	four	four	qn:&gt;7	@QN&gt; %&gt;N NUM CARD
         6	mammalian	mammalian	attr:&gt;7	@A&gt; %&gt;N A ABS
         7	genes	gene	pcomp:&gt;4	@&lt;P %NH N NOM PL
         8	that	that	subj:&gt;9	@SUBJ %NH &lt;Rel&gt; PRON
         9	encode	encode	mod:&gt;7	@+FMAINV %VA V PRES
         10	multiple	multiple	attr:&gt;11	@A&gt; %&gt;N A ABS
         11	PDE4	pde4	attr:&gt;12	@A&gt; %&gt;N N NOM SG
         12	cyclic	cyclic	attr:&gt;13	@A&gt; %&gt;N A ABS
         13	AMP-specific	amp-specific	attr:&gt;14	@A&gt; %&gt;N A ABS
         14	phosphodiesterase	phosphodiesterase	attr:&gt;15	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         15	isoforms	isoform	obj:&gt;9	@OBJ %NH &lt;?&gt; N NOM PL
         16	that	that	subj:&gt;17	@SUBJ %NH &lt;Rel&gt; PRON
         17	are	be	v-ch:&gt;18	@+FAUXV %AUX V PRES
         18	inhibited	inhibit	mod:&gt;15	@-FMAINV %VP EN
         19	by	by	agt:&gt;18	@ADVL %EH PREP
         20	rolipram	rolipram	pcomp:&gt;19	@&lt;P %NH &lt;?&gt; N NOM SG
         21	.     .
</fdg>
</example>
<example src="MEDLINE" no="3">
<text>
Nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits platelet function.

</text>
       <arg n="0">Nitric oxide
</arg>
       <arg n="1">-
</arg>
       <arg n="2">platelet function
</arg>
<fdg>
         
         1	Nitric	nitric	attr:&gt;2	@A&gt; %&gt;N A ABS
         2	oxide	oxide	subj:&gt;6	@SUBJ %NH N NOM SG
         3	(	(
         4	NO	no		@ADVL %EH ADV
         5	)	)
         6	activates	activate	main:&gt;0	@+FMAINV %VA V PRES SG3
         7	the	the	det:&gt;9	@DN&gt; %&gt;N DET
         8	soluble	soluble	attr:&gt;9	@A&gt; %&gt;N A ABS
         9	isoform	isoform	obj:&gt;6	@OBJ %NH &lt;?&gt; N NOM SG
         10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
         11	guanylate	guanylate	attr:&gt;12	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         12	cyclase	cyclase	pcomp:&gt;10	@&lt;P %NH &lt;?&gt; N NOM SG
         13	in	in	mod:&gt;12	@&lt;NOM %N&lt; PREP
         14	platelets	platelet	pcomp:&gt;13	@&lt;P %NH N NOM PL
         15	and	and	cc:&gt;6	@CC %CC CC
         16	inhibits	inhibit	cc:&gt;6	@+FMAINV %VA V PRES SG3
         17	platelet	platelet	attr:&gt;18	@A&gt; %&gt;N N NOM SG
         18	function	function	obj:&gt;16	@OBJ %NH N NOM SG
         19	.     .
</fdg>
</example>
<example src="MEDLINE" no="4">
<text>
Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity.

</text>
       <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies
</arg>
       <arg n="1">-
</arg>
       <arg n="2">NK-cell-mediated cytotoxicity
</arg>
<fdg>
         1	Natural	natural	attr:&gt;2	@A&gt; %&gt;N A ABS
         2	killer	killer		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@A&gt; %&gt;N N NOM SG
         3	(	(
         4	NK	nk		@NH %NH ABBR NOM SG
         5	)	)
         6	cells	cell	subj:&gt;7	@SUBJ %NH N NOM PL
         7	express	express	main:&gt;0	@+FMAINV %VA V PRES
         8	cell-surface	cell-surface	attr:&gt;9	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         9	receptors	receptor	obj:&gt;7	@OBJ %NH N NOM PL
         10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
         11	the	the	det:&gt;16	@DN&gt; %&gt;N DET
         12	immunoglobulin	immunoglobulin	cc:&gt;14	@A&gt; %&gt;N N NOM SG
         13	and	and	cc:&gt;14	@CC %CC CC
         14	C-type	c-type	attr:&gt;15	@A&gt; %&gt;N N NOM SG
         15	lectin	lectin	attr:&gt;16	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         16	superfamilies	superfamily	pcomp:&gt;10	@&lt;P %NH N NOM PL
         17	that	that	subj:&gt;18	@SUBJ %NH &lt;Rel&gt; PRON
         18	recognize	recognize	mod:&gt;16	@+FMAINV %VA V PRES
         19	major	major	attr:&gt;20	@A&gt; %&gt;N A ABS
         20	histocompatibility	histocompatibility	attr:&gt;21	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         21	complex	complex	attr:&gt;25	@A&gt; %&gt;N A ABS
         22	(	(
         23	MHC	mhc		@NH %NH ABBR NOM SG
         24	)	)
         25	class	class	obj:&gt;18	@OBJ %NH N NOM
         26	I	i		@SUBJ %NH PRON PERS NOM SG1
         27	peptides	peptide		@NH %NH N NOM PL	@OBJ %NH N NOM PL	@APP %NH N NOM PL
         28	and	and	cc:&gt;18	@CC %CC CC
         29	inhibit	inhibit	cc:&gt;18	@+FMAINV %VA V PRES
         30	NK-cell-mediated	nk-cell-mediated	attr:&gt;31	@A&gt; %&gt;N N NOM SG
         31	cytotoxicity	cytotoxicity	obj:&gt;29	@OBJ %NH N NOM SG
         32	.     .
</fdg>
</example>
<example src="MEDLINE" no="5">
<text>
Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and protein extracts from the transfected COS cells inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.

</text>
       <arg n="0">protein extracts from the transfected COS cells 
</arg>
       <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit
</arg>
       <arg n="2">-
</arg>
<fdg>
         1	Transient	transient	attr:&gt;2	@A&gt; %&gt;N A ABS
         2	overexpression	overexpression		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG
         3	in	in	mod:&gt;2	@&lt;NOM %N&lt; PREP
         4	COS	cos	pm:&gt;6	@CS %CS CS
         5	cells	cell	subj:&gt;6	@SUBJ %NH N NOM PL
         6	verified	verify		@+FMAINV %VA V PAST
         7	that	that	pm:&gt;15	@CS %CS CS
         8	a	a	det:&gt;10	@DN&gt; %&gt;N DET SG
         9	heat-stable	heat-stable	attr:&gt;10	@A&gt; %&gt;N &lt;?&gt; A ABS
         10	inhibitor	inhibitor	subj:&gt;14	@SUBJ %NH N NOM SG
         11	of	of	mod:&gt;10	@&lt;NOM-OF %N&lt; PREP
         12	protein	protein	attr:&gt;13	@A&gt; %&gt;N N NOM SG
         13	kinase	kinase	pcomp:&gt;11	@&lt;P %NH N NOM SG
         14	was	be	v-ch:&gt;15	@+FAUXV %AUX V PAST
         15	produced	produce		@-FMAINV %VP EN
         16	by	by	ha:&gt;15	@ADVL %EH ADV
         17	he	he		@SUBJ %NH PRON PERS NOM SG3
         18	human	human	attr:&gt;19	@A&gt; %&gt;N A ABS
         19	PKI	pki	attr:&gt;20	@A&gt; %&gt;N N NOM SG
         20	cDNA	cdna	obj:&gt;15	@OBJ %NH ABBR NOM SG
         21	,	,
         22	and	and	cc:&gt;15	@CC %CC CC
         23	protein	protein	subj:&gt;24	@SUBJ %NH N NOM SG
         24	extracts	extract	cc:&gt;15	@+FMAINV %VA V PRES SG3
         25	from	from	sou:&gt;24	@ADVL %EH PREP
         26	the	the	det:&gt;29	@DN&gt; %&gt;N DET
         27	transfected	transfected	attr:&gt;28	@A&gt; %&gt;N A ABS
         28	COS	cos	attr:&gt;29	@A&gt; %&gt;N ABBR NOM SG
         29	cells	cell	pcomp:&gt;25	@&lt;P %NH N NOM PL
         30	inhibited	inhibit	mod:&gt;29	@-FMAINV %VP EN
         31	both	both	det:&gt;32	@DN&gt; %&gt;N DET PL
         32	the	the	det:&gt;34	@DN&gt; %&gt;N DET
         33	C	c	attr:&gt;34	@A&gt; %&gt;N N NOM SG
         34	alpha	alpha	obj:&gt;30	@OBJ %NH N NOM SG
         35	and	and	cc:&gt;34	@CC %CC CC
         36	C	c	attr:&gt;37	@A&gt; %&gt;N N NOM SG
         37	beta	beta	attr:&gt;38	@A&gt; %&gt;N N NOM SG
         38	isoforms	isoform	cc:&gt;34	@OBJ %NH &lt;?&gt; N NOM PL
         39	of	of	mod:&gt;38	@&lt;NOM-OF %N&lt; PREP
         40	the	the	det:&gt;43	@DN&gt; %&gt;N DET
         41	PKA	pka	attr:&gt;42	@A&gt; %&gt;N N NOM SG
         42	catalytic	catalytic	attr:&gt;43	@A&gt; %&gt;N A ABS
         43	subunit	subunit	pcomp:&gt;39	@&lt;P %NH N NOM SG
         44	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
         45	equal	equal	attr:&gt;46	@A&gt; %&gt;N A ABS
         46	efficacy	efficacy	pcomp:&gt;44	@&lt;P %NH N NOM SG
         47	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.

</text>
       <arg n="0">[by] proteasome inhibitors MG132 and lactacystin
</arg>
       <arg n="1">-
</arg>
       <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6
</arg>
<fdg>
1	Here	here	loc:&gt;5	@ADVL %EH ADV
2	,	,
3	we	we	subj:&gt;4	@SUBJ %NH PRON PERS NOM PL1
4	have	have	v-ch:&gt;5	@+FAUXV %AUX V PRES
5	found	find	main:&gt;0	@-FMAINV %VA EN
6	that	that	pm:&gt;17	@CS %CS CS
7	the	the	det:&gt;8	@DN&gt; %&gt;N DET
8	downregulation	downregulation	subj:&gt;16	@SUBJ %NH N NOM SG
9	of	of	mod:&gt;8	@&lt;NOM-OF %N&lt; PREP
10	phosphorylated	phosphorylated	attr:&gt;11	@A&gt; %&gt;N A ABS
11	Stat4	stat4	pcomp:&gt;9	@&lt;P %NH N NOM SG
12	,	,
13	Stat5	stat5	cc:&gt;11	@&lt;P %NH N NOM SG
14	and	and	cc:&gt;13	@CC %CC CC
15	Stat6	stat6	cc:&gt;13	@&lt;P %NH N NOM SG
16	is	be	v-ch:&gt;17	@+FAUXV %AUX V PRES SG3
17	inhibited	inhibit	obj:&gt;5	@-FMAINV %VP EN
18	by	by	ha:&gt;17	@ADVL %EH PREP
19	the	the	det:&gt;22	@DN&gt; %&gt;N DET
20	proteasome	proteasome	attr:&gt;21	@A&gt; %&gt;N &lt;?&gt; N NOM SG
21	inhibitors	inhibitor	attr:&gt;22	@A&gt; %&gt;N N NOM PL
22	MG132	mg132	pcomp:&gt;18	@&lt;P %NH N NOM SG
23	and	and	cc:&gt;22	@CC %CC CC
24	lactacystin	lactacystin	cc:&gt;22	@&lt;P %NH &lt;?&gt; N NOM SG
25	,	,
26	while	while	tmp:&gt;36	@ADVL %EH ADV WH
27	the	the	det:&gt;28	@DN&gt; %&gt;N DET
28	downregulation	downregulation	subj:&gt;36	@SUBJ %NH N NOM SG
29	of	of	mod:&gt;28	@&lt;NOM-OF %N&lt; PREP
30	phosphorylated	phosphorylated	attr:&gt;31	@A&gt; %&gt;N A ABS
31	Stat1	stat1	pcomp:&gt;29	@&lt;P %NH N NOM SG
32	,	,
33	Stat2	stat2	cc:&gt;31	@&lt;P %NH N NOM SG
34	and	and	cc:&gt;33	@CC %CC CC
35	Stat3	stat3	cc:&gt;33	@&lt;P %NH N NOM SG
36	is	be	tmp:&gt;17	@+FMAINV %VA V PRES SG3
37	not	not	neg:&gt;36	@ADVL %EH NEG-PART
38	sensitive	sensitive	comp:&gt;36	@PCOMPL-S %NH A ABS
39	to	to	goa:&gt;36	@ADVL %EH PREP
40	these	this	det:&gt;41	@DN&gt; %&gt;N DET DEM PL
41	inhibitors	inhibitor	pcomp:&gt;39	@&lt;P %NH N NOM PL
42	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
For example, the phosphatase may associate with another protein and thereby be inhibited in its function or localization.

</text>
       <arg n="0">the phosphatase
</arg>
       <arg n="1">another protein 
</arg>
       <arg n="2">its function or localization
</arg>
<fdg>
1	For example	for example	meta:&gt;6	@ADVL %EH ADV
2	,	,
3	the	the	det:&gt;4	@DN&gt; %&gt;N DET
4	phosphatase	phosphatase	subj:&gt;5	@SUBJ %NH N NOM SG
5	may	may	v-ch:&gt;6	@+FAUXV %AUX V AUXMOD
6	associate	associate	main:&gt;0	@-FMAINV %VA V INF
7	with	with	phr:&gt;6	@ADVL %EH PREP
8	another	another	det:&gt;9	@DN&gt; %&gt;N DET
9	protein	protein	pcomp:&gt;7	@&lt;P %NH N NOM SG
10	and	and	cc:&gt;6	@CC %CC CC
11	thereby	thereby	meta:&gt;13	@ADVL %EH ADV
12	be	be	v-ch:&gt;13	@-FAUXV %AUX V INF
13	inhibited	inhibit	cc:&gt;6	@-FMAINV %VP EN
14	in	in	loc:&gt;13	@ADVL %EH PREP
15	its	it	attr:&gt;16	@A&gt; %&gt;N PRON GEN SG3
16	function	function	pcomp:&gt;14	@&lt;P %NH N NOM SG
17	or	or	cc:&gt;16	@CC %CC CC
18	localization	localization	cc:&gt;16	@&lt;P %NH N NOM SG
19	.     . 
</fdg>
</example>
<example src="EMBO" no="3">
<text>
The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, specifically inhibits intermediate events leading to the formation of clathrin-coated pits.

</text>
       <arg n="0">The N-terminal SH3 domain
</arg>
       <arg n="1">-
</arg>
       <arg n="2">intermediate events
</arg>
<fdg>
1	The	the	det:&gt;4	@DN&gt; %&gt;N DET
2	N-terminal	n-terminal	attr:&gt;3	@A&gt; %&gt;N A ABS
3	SH3	sh3	attr:&gt;4	@A&gt; %&gt;N N NOM SG
4	domain	domain		@NH %NH N NOM SG	@SUBJ %NH N NOM SG
5	(	(
6	SH3A	sh3a	mod:&gt;4	@NH %NH N NOM SG
7	)	)
8	,	,
9	unlike	unlike		@ADVL %EH PREP
10	other	other	det:&gt;12	@DN&gt; %&gt;N DET
11	SH3	sh3	attr:&gt;12	@A&gt; %&gt;N N NOM SG
12	domains	domain	pcomp:&gt;9	@&lt;P %NH N NOM PL
13	from	from	mod:&gt;12	@&lt;NOM %N&lt; PREP
14	intersectin	intersectin	pcomp:&gt;13	@&lt;P %NH &lt;?&gt; N NOM SG
15	or	or	cc:&gt;14	@CC %CC CC
16	various	various	attr:&gt;17	@A&gt; %&gt;N A ABS
17	endocytic	endocytic	attr:&gt;18	@A&gt; %&gt;N A ABS
18	proteins	protein	cc:&gt;14	@&lt;P %NH N NOM PL
19	,	,
20	specifically	specifically	ha:&gt;21	@ADVL %EH ADV
21	inhibits	inhibit	main:&gt;0	@+FMAINV %VA V PRES SG3
22	intermediate	intermediate	attr:&gt;23	@A&gt; %&gt;N A ABS
23	events	event	obj:&gt;21	@OBJ %NH N NOM PL
24	leading	lead	mod:&gt;23	@-FMAINV %VA ING
25	to	to	ha:&gt;24	@ADVL %EH PREP
26	the	the	det:&gt;27	@DN&gt; %&gt;N DET
27	formation	formation	pcomp:&gt;25	@&lt;P %NH N NOM SG
28	of	of	mod:&gt;27	@&lt;NOM-OF %N&lt; PREP
29	clathrin	clathrin	pcomp:&gt;28	@&lt;P %NH &lt;?&gt; N NOM SG
30	-	-
31	&lt;s&gt;	&lt;s&gt;
1	coated	coated	attr:&gt;2	@A&gt; %&gt;N A ABS
2	pits	pit		@APP %NH N NOM PL
3	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, selectively inhibit late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).

</text>
       <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I
</arg>
       <arg n="1">-
</arg>
       <arg n="2">late events of clathrin-coated vesicle formation
</arg>
<fdg>
         
1	Intriguingly	intriguingly		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
2	,	,
3	while	while		@ADVL %EH ADV WH	@&lt;P %NH ADV WH
4	the	the	det:&gt;8	@DN&gt; %&gt;N DET
5	SH3C	sh3c	cc:&gt;7	@A&gt; %&gt;N N NOM SG
6	and	and	cc:&gt;7	@CC %CC CC
7	SH3E	sh3e	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	domains	domain	subj:&gt;58	@SUBJ %NH N NOM PL
9	of	of	mod:&gt;8	@&lt;NOM-OF %N&lt; PREP
10	intersectin	intersectin	pcomp:&gt;9	@&lt;P %NH &lt;?&gt; N NOM SG
11	,	,
12	as well as	as well as	cc:&gt;10	@CC %CC CC
13	the	the	det:&gt;15	@DN&gt; %&gt;N DET
14	SH3	sh3	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	domains	domain	cc:&gt;10	@&lt;P %NH N NOM PL
16	from	from	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	the	the	det:&gt;20	@DN&gt; %&gt;N DET
18	endocytic	endocytic	attr:&gt;19	@A&gt; %&gt;N A ABS
19	proteins	protein	attr:&gt;20	@A&gt; %&gt;N N NOM PL
20	endophilin	endophilin	pcomp:&gt;16	@&lt;P %NH &lt;?&gt; N NOM SG
21	I	i		@SUBJ %NH PRON PERS NOM SG1
22	(	(
23	de	de		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
24	Heuvel	heuvel	pcomp:&gt;23	@&lt;P %NH N NOM SG
25	et	et		@CC %CC CC
26	al.	al.		@SUBJ %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
27	,	,
28	1997	1997		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@&lt;P %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
29	;	;
30	Ringstad	ringstad	main:&gt;29	@NH %NH &lt;?&gt; N NOM SG
31	et	et	cc:&gt;30	@CC %CC CC
32	al.	al.	cc:&gt;30	@NH %NH ABBR NOM SG
33	,	,
34	1997	1997	cc:&gt;32	@NH %NH NUM CARD
35	)	)
36	,	,
37	amphiphysin	amphiphysin		@NH %NH &lt;?&gt; N NOM SG	@SUBJ %NH &lt;?&gt; N NOM SG	@PCOMPL-S %NH &lt;?&gt; N NOM SG	@A&gt; %&gt;N &lt;?&gt; N NOM SG	@&lt;P %NH &lt;?&gt; N NOM SG
38	II	ii		@A&gt; %&gt;N NUM ORD	@PCOMPL-S %NH NUM ORD	@SUBJ %NH NUM ORD	@OBJ %NH NUM ORD	@ADVL %EH NUM ORD	@&lt;P %NH NUM ORD	@&lt;NOM %N&lt; NUM ORD
39	(	(
40	Ramjaun	ramjaun	main:&gt;39	@APP %NH &lt;?&gt; N NOM SG
41	et	et	cc:&gt;40	@CC %CC CC
42	al.	al.	cc:&gt;40	@APP %NH ABBR NOM SG
43	,	,
44	1997	1997	cc:&gt;42	@NH %NH NUM CARD
45	)	)
46	and	and		@CC %CC CC
47	syndapin	syndapin		@NH %NH &lt;?&gt; N NOM SG	@SUBJ %NH &lt;?&gt; N NOM SG	@OBJ %NH &lt;?&gt; N NOM SG	@PCOMPL-S %NH &lt;?&gt; N NOM SG	@APP %NH &lt;?&gt; N NOM SG	@&lt;P %NH &lt;?&gt; N NOM SG
48	I	i		@SUBJ %NH PRON PERS NOM SG1
49	(	(
50	Qualmann	qualmann	main:&gt;49	@APP %NH &lt;?&gt; N NOM SG
51	et	et	cc:&gt;50	@CC %CC CC
52	al.	al.	cc:&gt;50	@APP %NH ABBR NOM SG
53	,	,
54	1999	1999	cc:&gt;52	@NH %NH NUM CARD
55	)	)
56	,	,
57	selectively	selectively	ha:&gt;58	@ADVL %EH ADV
58	inhibit	inhibit		@+FMAINV %VA V PRES
59	late	late	attr:&gt;60	@A&gt; %&gt;N A ABS
60	events	event	obj:&gt;58	@OBJ %NH N NOM PL
61	of	of	mod:&gt;60	@&lt;NOM-OF %N&lt; PREP
62	clathrin-coated	clathrin-coated	attr:&gt;63	@A&gt; %&gt;N &lt;?&gt; A ABS
63	vesicle	vesicle	attr:&gt;64	@A&gt; %&gt;N N NOM SG
64	formation	formation	pcomp:&gt;61	@&lt;P %NH N NOM SG
65	involving	involve	mod:&gt;64	@-FMAINV %VA ING
66	membrane	membrane	attr:&gt;67	@A&gt; %&gt;N N NOM SG
67	fission	fission	obj:&gt;65	@OBJ %NH N NOM SG
68	,	,
69	intersectin	intersectin	attr:&gt;70	@A&gt; %&gt;N &lt;?&gt; N NOM SG
70	SH3A	sh3a	subj:&gt;71	@SUBJ %NH N NOM SG
71	was	be		@+FMAINV %VA V PAST
72	unique	unique	comp:&gt;71	@PCOMPL-S %NH A ABS
73	in	in	loc:&gt;71	@&lt;NOM %N&lt; PREP
74	its	it	attr:&gt;75	@A&gt; %&gt;N PRON GEN SG3
75	ability	ability	pcomp:&gt;73	@&lt;P %NH N NOM SG
76	to	to	pm:&gt;77	@INFMARK&gt; %AUX INFMARK&gt;
77	block	block	mod:&gt;75	@-FMAINV %VA V INF
78	earlier	early	attr:&gt;79	@A&gt; %&gt;N A CMP
79	stages	stage	obj:&gt;77	@OBJ %NH N NOM PL
80	(	(
81	Simpson	simpson	main:&gt;80	@APP %NH N NOM SG
82	et	et		@CC %CC CC
83	al.	al.		@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
84	,	,
85	1999	1999		@NH %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
86	)	)
87	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml chloramphenicol to inhibit protein synthesis.

</text>
       <arg n="0">chloramphenicol
</arg>
       <arg n="1">them
</arg>
       <arg n="2">protein synthesis
</arg>
<fdg>
1	The	the	det:&gt;2	@DN&gt; %&gt;N DET
2	half-life	half-life	subj:&gt;7	@SUBJ %NH N NOM SG
3	of	of	mod:&gt;2	@&lt;NOM-OF %N&lt; PREP
4	the	the	det:&gt;6	@DN&gt; %&gt;N DET
5	AGT	agt	attr:&gt;6	@A&gt; %&gt;N ABBR NOM SG
6	proteins	protein	pcomp:&gt;3	@&lt;P %NH N NOM PL
7	was	be	v-ch:&gt;8	@+FAUXV %AUX V PAST
8	determined	determine		@-FMAINV %VP EN
9	by	by	man:&gt;8	@ADVL %EH PREP
10	growing	grow	pcomp:&gt;9	@&lt;P-FMAINV %VA ING
11	cells	cell	obj:&gt;10	@OBJ %NH N NOM PL
12	at	at		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
13	37	37		@QN&gt; %&gt;N NUM CARD
14	C	c	pcomp:&gt;12	@&lt;P %NH N NOM SG
15	in	in	mod:&gt;14	@&lt;NOM %N&lt; PREP
16	LB	lb	attr:&gt;17	@A&gt; %&gt;N ABBR NOM SG
17	broth	broth	pcomp:&gt;15	@&lt;P %NH N NOM SG
18	supplemented	supplement	mod:&gt;17	@-FMAINV %VP EN
19	with	with	phr:&gt;18	@ADVL %EH PREP
20	50	50		@QN&gt; %&gt;N NUM CARD
21	µg	µg	pcomp:&gt;19	@&lt;P %NH N NOM SG
22	/	/	
23	ml	ml	attr:&gt;24	@A&gt; %&gt;N ABBR NOM
24	ampicillin	ampicillin		@A&gt; %&gt;N &lt;?&gt; N NOM SG
25	,	,
26	50	50		@QN&gt; %&gt;N NUM CARD
27	µg	µg		@APP %NH N NOM SG	@&lt;P %NH N NOM SG
28	/	/	
29	ml	ml	attr:&gt;30	@A&gt; %&gt;N ABBR NOM
30	kanamycin	kanamycin		@&lt;P %NH &lt;?&gt; N NOM SG
31	and	and	cc:&gt;30	@CC %CC CC
32	0.2	0.2	qn:&gt;33	@QN&gt; %&gt;N NUM CARD
33	mM	mm	attr:&gt;34	@A&gt; %&gt;N ABBR NOM
34	IPTG	iptg	cc:&gt;30	@&lt;P %NH N NOM SG
35	until	until	pm:&gt;38	@CS %CS CS
36	the	the	det:&gt;37	@DN&gt; %&gt;N DET
37	A600	a600	subj:&gt;38	@SUBJ %NH N NOM SG
38	reached	reach		@+FMAINV %VA V PAST
39	0.3	0.3	obj:&gt;38	@OBJ %NH NUM CARD
40	and	and	cc:&gt;38	@CC %CC CC
41	then	then	meta:&gt;42	@ADVL %EH ADV
42	treating	treat	cc:&gt;38	@-FMAINV %VA ING
43	them	they	obj:&gt;42	@OBJ %NH PRON PERS ACC PL3
44	with	with	com:&gt;42	@ADVL %EH PREP
45	50	50		@QN&gt; %&gt;N NUM CARD
46	µg	µg	pcomp:&gt;44	@&lt;P %NH N NOM SG
47	/	/	
48	ml	ml	attr:&gt;49	@A&gt; %&gt;N ABBR NOM
49	chloramphenicol	chloramphenicol		@SUBJ %NH &lt;?&gt; N NOM SG
50	to	to	pm:&gt;51	@INFMARK&gt; %AUX INFMARK&gt;
51	inhibit	inhibit	mod:&gt;49	@-FMAINV %VA V INF
52	protein	protein	attr:&gt;53	@A&gt; %&gt;N N NOM SG
53	synthesis	synthesis	obj:&gt;51	@OBJ %NH N NOM SG
54	.     .
</fdg>
</example>
<example src="EMBO" no="6">
<text>
Binding was concentration dependent and saturable and was totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.

</text>
       <arg n="0">[with] 10mM EDTA
</arg>
       <arg n="1">-
</arg>
       <arg n="2">Binding
</arg>
<fdg>
1	Binding	binding	subj:&gt;2	@SUBJ %NH A ABS
2	was	be	main:&gt;0	@+FMAINV %VA V PAST
3	concentration	concentration	comp:&gt;2	@PCOMPL-S %NH N NOM SG
4	dependent	dependent	mod:&gt;3	@&lt;NOM %N&lt; A ABS
5	and	and		@CC %CC CC
6	saturable	saturable		@PCOMPL-S %NH A ABS
7	and	and		@CC %CC CC
8	was	be	v-ch:&gt;10	@+FAUXV %AUX V PAST
9	totally	totally	meta:&gt;10	@ADVL %EH ADV
10	inhibited	inhibit		@-FMAINV %VP EN
11	with	with	ha:&gt;10	@ADVL %EH PREP
12	10	10	qn:&gt;13	@QN&gt; %&gt;N NUM CARD
13	mM	mm	pcomp:&gt;11	@&lt;P %NH ABBR NOM
14	EDTA	edta		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
15	,	,
16	suggesting	suggest	man:&gt;10	@-FMAINV %VA ING
17	that	that	pm:&gt;21	@CS %CS CS
18	divalent	divalent	attr:&gt;19	@A&gt; %&gt;N A ABS
19	cations	cation	subj:&gt;20	@SUBJ %NH N NOM PL
20	were	be	v-ch:&gt;21	@+FAUXV %AUX V PAST PL
21	required	require	obj:&gt;16	@-FMAINV %VP EN
22	for	for	ha:&gt;21	@ADVL %EH PREP
23	interaction	interaction	pcomp:&gt;22	@&lt;P %NH N NOM SG
24	of	of	mod:&gt;23	@&lt;NOM-OF %N&lt; PREP
25	InlB	inlb	pcomp:&gt;24	@&lt;P %NH N NOM SG
26	with	with	mod:&gt;25	@&lt;NOM %N&lt; PREP
27	Vero	vero	attr:&gt;28	@A&gt; %&gt;N &lt;?&gt; N NOM SG
28	cells	cell	pcomp:&gt;26	@&lt;P %NH N NOM PL
29	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
